These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 26666989

  • 1. Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).
    Donnier-Maréchal M, Vidal S.
    Expert Opin Ther Pat; 2016; 26(2):199-212. PubMed ID: 26666989
    [Abstract] [Full Text] [Related]

  • 2. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 3. Glycogen phosphorylase inhibitors: a patent review (2008 - 2012).
    Gaboriaud-Kolar N, Skaltsounis AL.
    Expert Opin Ther Pat; 2013 Aug 27; 23(8):1017-32. PubMed ID: 23627914
    [Abstract] [Full Text] [Related]

  • 4. Discovery and evaluation of novel benzazepinone derivatives as glycogen phosphorylase inhibitors with potent activity.
    Wang Y, Yan Z, Guo Y, Zhang L.
    Future Med Chem; 2021 May 27; 13(10):897-909. PubMed ID: 33906369
    [Abstract] [Full Text] [Related]

  • 5. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.
    Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P.
    Curr Pharm Des; 2003 May 27; 9(15):1177-89. PubMed ID: 12769745
    [Abstract] [Full Text] [Related]

  • 6. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Czifrák K, Larini P, Demontrond F, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Docsa T, Gergely P, Somsák L, Praly JP, Azay-Milhau J, Vidal S.
    Org Biomol Chem; 2020 Feb 07; 18(5):931-940. PubMed ID: 31922157
    [Abstract] [Full Text] [Related]

  • 7. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG, Somsák L.
    Curr Opin Investig Drugs; 2008 Apr 07; 9(4):379-95. PubMed ID: 18393105
    [Abstract] [Full Text] [Related]

  • 8. Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and GL-subunit of glycogen-associated protein phosphatase 1: WO2009127723.
    Zhang L, Liu H.
    Expert Opin Ther Pat; 2010 Jul 07; 20(7):969-73. PubMed ID: 20367521
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.
    Oikonomakos NG.
    Curr Protein Pept Sci; 2002 Dec 07; 3(6):561-86. PubMed ID: 12470212
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ, Greenhaff PL, MacInnes A, Timmons JA.
    Diabetes; 2006 Jun 01; 55(6):1855-61. PubMed ID: 16731853
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Synthesis, in vitro ADME profiling and in vivo pharmacological evaluation of novel glycogen phosphorylase inhibitors.
    Miao GX, Wang YD, Yan ZW, Zhang LY.
    Bioorg Med Chem Lett; 2020 Jul 15; 30(14):127117. PubMed ID: 32527535
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site.
    Praly JP, Vidal S.
    Mini Rev Med Chem; 2010 Oct 15; 10(12):1102-26. PubMed ID: 20716051
    [Abstract] [Full Text] [Related]

  • 20. 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why.
    Manta S, Xipnitou A, Kiritsis C, Kantsadi AL, Hayes JM, Skamnaki VT, Lamprakis C, Kontou M, Zoumpoulakis P, Zographos SE, Leonidas DD, Komiotis D.
    Chem Biol Drug Des; 2012 May 15; 79(5):663-73. PubMed ID: 22296957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.